Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman ...Middle East

SAN FRANCISCO, May 7, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective ("HERO") trial evaluating the...

Hence then, the article about aardvark therapeutics aard faces investor scrutiny amid 56 drop on clinical pause for lead drug candidate hagens berman was published today ( Thursday 07/05/2026 - 08:31 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman )

Also on site :

• No Doubt Transport Las Vegas Sphere to Orange County for New Residency: See Their Full Night 1 Setlist
• Iran imposes new rules for Strait of Hormuz in bid to secure wartime gains
• Quote of the Day: Trisha Yearwood Shares Her Secret to Self-Love